- Home
- GDL vs ZNTL Comparison
GDL vs ZNTL Comparison
Compare GDL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ZNTL
- Stock Information
- Founded
- GDL 2006
- ZNTL 2014
- Country
- GDL United States
- ZNTL United States
- Employees
- GDL N/A
- ZNTL N/A
- Industry
- GDL Investment Managers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- ZNTL Health Care
- Exchange
- GDL Nasdaq
- ZNTL Nasdaq
- Market Cap
- GDL 93.3M
- ZNTL 105.8M
- IPO Year
- GDL N/A
- ZNTL 2020
- Fundamental
- Price
- GDL $8.54
- ZNTL $1.45
- Analyst Decision
- GDL
- ZNTL Buy
- Analyst Count
- GDL 0
- ZNTL 7
- Target Price
- GDL N/A
- ZNTL $8.46
- AVG Volume (30 Days)
- GDL 11.2K
- ZNTL 776.4K
- Earning Date
- GDL 01-01-0001
- ZNTL 11-11-2025
- Dividend Yield
- GDL 6.02%
- ZNTL N/A
- EPS Growth
- GDL N/A
- ZNTL N/A
- EPS
- GDL N/A
- ZNTL N/A
- Revenue
- GDL N/A
- ZNTL $26,865,000.00
- Revenue This Year
- GDL N/A
- ZNTL N/A
- Revenue Next Year
- GDL N/A
- ZNTL N/A
- P/E Ratio
- GDL N/A
- ZNTL N/A
- Revenue Growth
- GDL N/A
- ZNTL N/A
- 52 Week Low
- GDL $7.65
- ZNTL $1.01
- 52 Week High
- GDL $8.13
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- GDL 51.91
- ZNTL 49.12
- Support Level
- GDL N/A
- ZNTL N/A
- Resistance Level
- GDL $8.64
- ZNTL $2.02
- Average True Range (ATR)
- GDL 0.04
- ZNTL 0.11
- MACD
- GDL -0.32
- ZNTL -0.10
- Stochastic Oscillator
- GDL 98.73
- ZNTL 70.80
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.